SAR-445136 is a Gene-Modified Cell Therapy owned by Sangamo Therapeutics, and is involved in 2 clinical trials, which are ongoing.
SAR-445136 is designed to directly regulate sickle cell anemia related genes. BCL11-A modified hematopoietic stem progenitor cells act by direct regulation of disease-related genes and ZFNs to disrupt or correct therapeutically relevant genes. ZFP TFs regulate the cellular copy of the gene and mimic the cell’s natural method of gene regulation turning on or off all of the natural forms of the gene product. The therapeitic candidate allows the body to manufacture red blood cells with an alternate form of hemoglobin unaffected by the mutation that causes the disease.
The revenue for SAR-445136 is expected to reach a total of $66m through 2038. This change impacts the valuation of this asset and is an important factor to understand the current value of the drug in a clinical process. View the complete picture with the SAR-445136 NPV Report.
SAR-445136 is originated and owned by Sangamo Therapeutics. Sanofi is the other company associated in development or marketing of SAR-445136.
SAR-445136 Overview
SAR-445136 is under development for the treatment of hemoglobinopathies including sickle cell anemia. The therapeutic candidate consists of autologous CD34 hematopoietic stem and progenitor cells transfected with zinc finger nuclease messenger RNAs SB-mRENH1 and SB-mRENH2 and is administered as an intravenous infusion. It is developed based on Zinc Finger Proteins (ZFPs) technology.
Sanofi Overview
Sanofi is a healthcare company, which is engaged in the discovery, development, manufacturing and marketing of a wide range of medicines and vaccines. Its portfolio includes medicines for the treatment of cancer, diabetes, rare diseases, multiple sclerosis and cardiovascular diseases; human vaccines for protection against various bacterial and viral diseases; and other products. The company also offers consumer healthcare products for digestion; allergy; cough, cold, flu and sinus; pain; women’s health; and vitamins, minerals and supplements. Sanofi‘s R&D efforts focus on advancing a combination drugs to increase the effectiveness of treatments and on advancing the formulation of new biologics to produce precision medicines. It has operations in Europe, the Americas, Asia-Pacific, Africa and the Middle East. Sanofi is headquartered in Paris, France.
The company reported revenues of (Euro) EUR39,175 million for the fiscal year ended December 2021 (FY2021), an increase of 4.8% over FY2020. In FY2021, the company’s operating margin was 20.7%, compared to an operating margin of 37.8% in FY2020. In FY2021, the company recorded a net margin of 15.9%, compared to a net margin of 32.9% in FY2020.
The company reported revenues of EUR13,138 million for the third quarter ended September 2022, a decrease of 36.8% over the previous quarter.
Quick View – SAR-445136
| Report Segments | |
| Drug Name | |
| Administration Pathway | |
| Therapeutic Areas | |
| Key Companies | |
| Highest Development Stage |
Source link
#Revenue #SAR445136 #expected #CAGR
